Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades

Mycoses

Volumn 54, Issue 1, 2011, Pages 34-38

  Bulik, C C ^a   Sobel, J D ^b   Nailor, M D ^c,d  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Candida albicans; Fluconazole; Minimum inhibitory concentration.; Vulvovaginal candidiasis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VAGINA;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; FEMALE; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; VAGINA;

CANDIDA ALBICANS;

EID: 78649837779     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01752.x     Document Type: Article

References (15)

1. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961-71.
2. Eckert LO. Acute Vulvovaginitis. NEJM 2006; 355: 1244-52.
3. Sobel JD, Zervos M, Reed BD et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother 2003; 47: 34-38.
4. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002; 99: 419-25.
5. Bauters TGM, Dhont MA, Temmerman MIL, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569-74.
6. Desai PC, Johnson BA. Oral fluconazole for vaginal candidiasis. Am Fam Physician 1996; 54: 1337-440.
7. Houang ET, Chappatte O, Byrne D, Macrae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990; 34: 909-10.
8. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990; 39: 877-916.
9. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735-45.
10. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. NCCLS document M27-A (ISBN 1-56238-328-0). PA: NCCLS, 1997.
11. Ritter W, Patzschke K, Krause U, Stettendorf S. Pharmacokinetic fundamentals of vaginal treatment with clotrimazole. Chemotherapy 1982; 28: 37-42.
12. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-47.
13. Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006; 57: 384-410.
14. Moosa MY, Sobel JD, Elhalis H, Du W, Akins RA. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina simulative media. Antimicrob Agents Chemother 2004; 48: 161-7.
15. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-62.